Loading news...
Biohaven Ltd. shares surged 3.42% in after-hours trading following an SEC filing that detailed investor presentations and updates on its drug pipeline.
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to date: IgA Nephropathy (IgAN) Program: First dosing of BHV-1400 TRAP degrader in IgAN patients achieved early observations of both biomarker and clinical responses including: selective lowering of only the disease-causing galactose-deficient IgA1 (Gd-IgA1) while sparing off-target effects on healthy antibodies (IgA, IgM, IgE, IgG), resolution of blood in the urine (hematuria), deep reductions in proteinuria, and improvement in fatigue and kidney function (eGFR) within weeks.
NEW HAVEN, Conn., Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd.
Biohaven Ltd (NYSE:BHVN) stock is down 3.2% to trade at $10.46 at last glance, amid reports that the biopharmaceutical name's drug to treat major depressive disorder did not meet the primary goal of a phase 2 trial.
BHVN's investment case definitely weakened after Opakalim's Phase 2 MDD miss. This also means they'll discontinue their psychiatric development. BHVN's pipeline remains diverse, but key assets like Opakalim for depression and Taldefgrobep alfa for SMA missed primary endpoints. Current cash runway is approximately 3.1 quarters, heightening urgency for successful near-term clinical milestones and FDA approvals.
Stock futures are quiet as investors return from Christmas, with all three major indexes eyeing weekly gains
On Wednesday, Biohaven Ltd. (NYSE: BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for major depressive disorder (MDD).
U.S. stock futures slipped on Friday after Wednesday's higher close. Futures of major benchmark indices fell.
US stock futures slightly lower. Stocks to watch: NVIDIA, Dynavax, Sobr Safe, Davis Commodities, Biohaven.
ARS Investment Partners LLC decreased its stake in shares of Biohaven Ltd. (NYSE: BHVN) by 7.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,102,549 shares of the company's stock after selling 85,577 shares during the quarter. Biohaven comprises about
Biohaven shares fell 16.19% in after-hours trading Wednesday after its Phase 2 depression drug trial missed the primary endpoint.
Biohaven said on Wednesday its experimental depression drug did not meet the main goal of a mid-stage trial, adding to a string of trial and regulatory setbacks for the drugmaker this year.
NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd.
The consensus price target hints at an 88.6% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Biohaven Ltd. (BHVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective response rates 3/5 (60%) in NSCLC, 4/4 (100%) in endometrial cancer, and 1/2 (50%) in urothelial cancer There were low rates of adverse events attributed to unconjugated payload such as hematological toxicities and diarrhea, and there were no cases of interstitial lung disease, showing a differentiated safety profile of BHV-1510 from other Trop2 ADCs BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates encouraging early clinical activity and favorable safety profile in a Phase 1 study in combination with the anti-PD-1 cemiplimab LONDON and NEW HAVEN, Conn. , Dec. 11, 2025 /PRNewswire/ -- Biohaven Ltd.
The average of price targets set by Wall Street analysts indicates a potential upside of 127.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NASDAQ leading the way, closing up 0.59% at 23,413. The S&P 500 ended the session at 6,829, up 0.25% and the Dow Jones Industrials... Here Are Wednesday's Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy's and More.
AXQ Capital LP grew its stake in shares of Biohaven Ltd. (NYSE: BHVN) by 59.8% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,602 shares of the company's stock after buying an additional 6,587 shares during the period. AXQ Capital LP's holdings
When corporate executives make multi-million-dollar personal investments in the company they lead, it is one of the most potent signals an investor can receive. At Biohaven NYSE: BHVN, that signal has just been sent loud and clear.